---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43267128.md"
description: "$Iovance Biotherapeautics(IOVA.US) rose +43%, with Q2 revenue at $99.31 million, up 66% year-over-year, and operating losses narrowing to $51.91 million; $Caris Life Sciences(CAI.US) rose +22%, with Q2 revenue of $264 million beating expectations and full-year guidance raised. Both delivered solid revenue growth, but the question is: since so much of the expectation was already priced in on earnings day, how much room is left? The ramp-up curve for Amtagvi has just begun, and the upward revision in molecular diagnostics hasn't been fully priced in yet. From a fundamental perspective, it's far from the peak. However, entering after a single-day 40% surge means your cost basis is no longer attractive—first see if it can hold above the 30-day moving average during a pullback, then decide whether to add."
datetime: "2026-08-07T09:41:59.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43267128.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43267128.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43267128.md)
author: "[好事连连](https://longbridge.com/en/profiles/27514675.md)"
---

# $Iovance Biotherapeautics(IOVA.US) rose +43%, with…


### Related Stocks

- [CAI.US](https://longbridge.com/en/quote/CAI.US.md)
- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)